Exodus Point Capital Management, LP Glaukos Corp Transaction History

Exodus Point Capital Management, LP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$69.23 - $79.09 $564,086 - $644,425	-8,148 Reduced 30.98%	18,157 $1.37 Million
Q2 2023 Aug 10, 2023	BUY	$45.44 - $71.21 $1.2 Million - $1.87 Million	26,305 New	26,305 $1.87 Million
Q4 2022 Feb 13, 2023	BUY	$40.82 - $57.75 $1.25 Million - $1.77 Million	30,637 New	30,637 $1.34 Million
Q3 2022 Nov 10, 2022	SELL	$46.84 - $58.49 $269,517 - $336,551	-5,754 Closed	0 $0
Q2 2022 Aug 19, 2022	BUY	$34.86 - $63.77 $200,584 - $366,932	5,754 New	5,754 $261,000
Q4 2021 Feb 11, 2022	SELL	$40.27 - $56.99 $612,063 - $866,191	-15,199 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$47.43 - $84.23 $720,888 - $1.28 Million	15,199 New	15,199 $732,000
Q2 2021 Aug 16, 2021	SELL	$73.06 - $97.7 $602,452 - $805,634	-8,246 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$70.43 - $97.42 $2.62 Million - $3.62 Million	-37,158 Reduced 81.84%	8,246 $692,000
Q4 2020 Feb 16, 2021	BUY	$48.9 - $75.26 $2.22 Million - $3.42 Million	45,404 New	45,404 $3.42 Million
Q3 2020 Nov 16, 2020	SELL	$37.23 - $50.97 $972,261 - $1.33 Million	-26,115 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$28.78 - $46.83 $751,589 - $1.22 Million	26,115 New	26,115 $1 Million
Q1 2020 May 15, 2020	SELL	$25.53 - $70.14 $124,280 - $341,441	-4,868 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$54.18 - $65.64 $263,748 - $319,535	4,868 New	4,868 $265,000
Q1 2019 May 15, 2019	SELL	$50.75 - $80.54 $504,302 - $800,325	-9,937 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$52.18 - $67.93 $518,512 - $675,020	9,937 New	9,937 $558,000

341

46.8M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.18B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.